Ivor the Engineer
Penultimate Amazing
- Joined
- Feb 18, 2006
- Messages
- 10,600
http://www.independent.co.uk/life-s...0-now-nhs-drugs-body-recalculates-958708.html
I can't wait to see the algorithm used to determine how much blame to attatch to patients and how it will affect the choice of treatments they are offered.
What price a life? The controversial National Institute for Clinical Excellence (Nice) is about to decide. Under bitter attack for denying life-extending drugs for conditions such as cancer and dementia, the body is to revolutionise how it chooses which vital life- saving drugs are funded by the NHS.
For the past nine years, Nice has come under attack repeatedly over the medications it approves or denies for NHS patients. Only yesterday, Carol Rummels won the right to a cancer drug called Tarceva denied by Nice and which she has been paying for herself. Now, South Gloucestershire Primary Care Trust has agreed to pay £1,500 a month for the drug which is available for free in Scotland, where Nice doesn't rule.
On Tuesday, the world will have its first glimpse into how the system might change: new research by leading UK health economists will raise serious questions about the way Nice makes its decisions and suggest how it might change.
...
The research from Newcastle University, commissioned by Nice and to be published in the journal Health Economics, will criticise the system for failing to take into account public opinion. The new maths calculates the figure by asking people their willingness to pay for health and what they would sacrifice to have it.
Another new study by Imperial College found that the current system fails to capture the real impact of devastating health problems on patients and their families. It says that the public wants Nice to consider age, type of illness and, most controversially, the extent to which patients themselves, or the NHS, must bear some of the blame. This array of new research means that Nice will have to abandon a "one size fits all" system of valuing patients' lives and adopt a more radical approach.
Nice has revealed that it plans to move quickly to implement some of the findings. Experts will meet in February to discuss the benchmark figure Nice currently uses to approve drugs. Meanwhile, the drug appraisal committees at Nice have been instructed to take into account the new evidence about the public's priorities. Work will begin to improve the way the QALY is calculated. The body's citizens' council will begin the process next month.
...
I can't wait to see the algorithm used to determine how much blame to attatch to patients and how it will affect the choice of treatments they are offered.